Skip to main content
    G

    Gain Therapeutics Inc (GANX)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $0.94
    -0.10 (-9.60%)

    Market Cap: $46.31M

    Last updated: Nov 17, 2026 at 11:06 AM ET

    Gain Therapeutics Inc (GANX) Stock Forecast

    Updated Nov 17, 2026. Estimates and ratings come from consensus analyst data.

    Analysts expect Gain Therapeutics (GANX) to earn -$0.40 per share in the fiscal year ending Dec 31, 2026. Of 5 analysts, 5 rate the stock Buy or Strong Buy, 0 Hold and 0 Sell or Strong Sell, for a consensus of Buy. For the fiscal year ending Dec 31, 2027, the EPS consensus is -$0.63.

    Analyst Ratings

    Scoring Strong Buy as 1 and Strong Sell as 5, the 5 ratings average 1.80, inside the Buy band from 1.5 up to 2.5. Buy and Strong Buy make up 100% of the ratings.

    RatingAnalystsShare
    Strong Buy120.0%
    Buy480.0%
    Hold00.0%
    Sell00.0%
    Strong Sell00.0%
    Consensus
    Buy
    Total analysts
    5

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    Annual Estimates

    From the first fiscal year below to the second, the EPS consensus shows a larger loss.

    Fiscal year ending Dec 31, 2026
    -$0.40
    EPS consensus
    Fiscal year ending Dec 31, 2027
    -$0.63
    EPS consensus
    Next report
    Mar 24, 2027
    Estimated

    EPS range

    Fiscal year endingEPS consensusEPS rangeEPS analysts
    Dec 31, 2026-$0.40-$0.41 to -$0.382
    Dec 31, 2027-$0.63-$1.00 to -$0.354

    Quarterly Estimates

    The EPS consensus rises from -$0.13 for the quarter ending Dec 31, 2026 to -$0.12 for the quarter ending Mar 31, 2027.

    EPS range

    Quarter endingEPS consensusEPS rangeEPS analysts
    Dec 31, 2026-$0.13-$0.16 to -$0.086
    Mar 31, 2027-$0.12-$0.13 to -$0.113

    Estimate Revisions

    Across the 3 periods below, the last 30 days brought 3 upward and 1 downward EPS revisions.

    PeriodUp 30 daysDown 30 days
    Fiscal year ending Dec 31, 202600
    Fiscal year ending Dec 31, 202721
    Quarter ending Mar 31, 202710

    EPS Trend

    Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has improved from -$0.59.

    PeriodNow7 days ago30 days ago60 days ago90 days agoChange
    Fiscal year ending Dec 31, 2026-$0.40-$0.51-$0.51-$0.50-$0.59N/A
    Fiscal year ending Dec 31, 2027-$0.63-$0.69-$0.69-$0.55-$0.57N/A
    Quarter ending Mar 31, 2027-$0.12-$0.13-$0.13-$0.13-$0.13N/A

    Frequently Asked Questions About GANX

    What is the GANX stock forecast?

    Consensus analyst estimates put Gain Therapeutics's EPS at -$0.40 for the fiscal year ending Dec 31, 2026. The consensus rating from 5 analysts is Buy.

    How do analysts rate GANX stock?

    Of 5 analysts covering Gain Therapeutics, 1 rates it Strong Buy, 4 Buy, 0 Hold, 0 Sell and 0 Strong Sell, for a consensus of Buy.

    What EPS do analysts expect from GANX next year?

    For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is -$0.40, with estimates from -$0.41 to -$0.38 from 2 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is -$0.63, with estimates from -$1.00 to -$0.35 from 4 analysts.

    How many analysts cover GANX?

    5 analysts rate Gain Therapeutics stock, and 2 analysts estimate its EPS for the fiscal year ending Dec 31, 2026.